|
Status |
Public on Jul 21, 2016 |
Title |
Scr SID 1 |
Sample type |
RNA |
|
|
Source name |
231 breast cancer cell line
|
Organism |
Homo sapiens |
Characteristics |
cell type: Breast cancer cell line
|
Treatment protocol |
MDA-MB-231 cells were treated with scrambled SID control, 2.5µM SID peptide or untreated for 24h.
|
Growth protocol |
MDA-MB-231 cell lines were maintained in DMEM supplemented with 10% FBS, 1% GlutaMAX (Invitrogen), 10mM HEPES, 1mM sodium pyruvate, non-essential amino acids and 1% antibiotic-antimycotic solution.
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated using the ZR RNA MiniPrep Kit (Zymo Research). The concentration and quality of the total RNA was assessed on an Agilent 2100 BioAnalyzer (Agilent Technologies).
|
Label |
biotin
|
Label protocol |
All samples were normalized to 200ng and processed according to standard Affymetrix protocols using GeneChip WT Terminal Labeling and Controls Kit (Affymetrix) and WT Expression Kit (Ambion).
|
|
|
Hybridization protocol |
The quality and quantity of labeled cRNA was checked and 750 ng of labeled cRNA were hybridized to a GeneChip Human Gene 1.0 ST Arrays using GeneChip Hybridization, Wash, and Stain Kit (Affymetrix).
|
Scan protocol |
The arrays were scanned on a GeneChip Scanner 3000 7G.
|
Data processing |
Raw data were processed with the Expression Console (Affymetrix) for background correction and normalization using RMA algorithm. Secondary analysis of the data was performed by Transcriptome analysis console (Affymetrix).
|
|
|
Submission date |
Jul 20, 2016 |
Last update date |
Jul 21, 2016 |
Contact name |
Kevin Petrie |
E-mail(s) |
kevin.petrie@stir.ac.uk
|
Phone |
+44 1786 466840
|
Organization name |
University of Stirling
|
Department |
Biological and Environmental Sciences
|
Street address |
Stirling
|
City |
Stirling |
State/province |
Stirling |
ZIP/Postal code |
FK9 4LA |
Country |
United Kingdom |
|
|
Platform ID |
GPL6244 |
Series (1) |
GSE84648 |
Targeted interference of sin3a-tgif1 function by SID decoy treatment inhibits WNT signaling and invasion in triple negative breast cancer cells |
|